Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1045 results
May 2022
-
Media ReleaseSandoz appoints new Board representative to global AMR Industry AllianceDr. Boumediene Soufi, global head of Sandoz AMR (antimicrobial resistance) program, to represent Sandoz as Board member of AMR Industry Alliance (AMRIA)The Alliance brings together about 100 life…
-
Media ReleaseNovartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditionsPositive opinion could expand the role of Cosentyx®(secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EUSafety in these…
-
Media ReleaseNovartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancerLatest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali® plus endocrine therapy, further MONALEESA-2 quality of life and overall survival analyses, and a new…
-
Media ReleaseNovartis provides update on production of radioligand therapy medicinesNovartis has temporarily suspended production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at facilities in Ivrea, Italy and Millburn, New JerseyThis action has been taken out of an abundance of…
-
Media ReleaseNovartis receives European Commission approval for Jakavi® to be the first post-steroid treatment for acute and chronic graft-versus-host diseaseJakavi is the first JAK1/2 inhibitor available for patients in Europe who previously had no approved therapies for the treatment of steroid-refractory graft-versus-host disease (GvHD)1,2 In clinical…
-
Media ReleaseNew Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patientsWith further follow-up of MONALEESA-3, Kisqali plus fulvestrant achieved a median overall survival (OS) of more than five-and-a-half years (67.6 months) in the first-line (1L) setting for…
-
Media ReleaseNovartis Kymriah® receives EC approval as first CAR-T cell therapy for adults with relapsed or refractory follicular lymphomaKymriah offers patients in Europe with advanced follicular lymphoma a potentially definitive, single infusion CAR-T cell therapy with a remarkable safety profile Approval based on the Phase II…
April 2022
-
Media ReleaseNovartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III studyRATIONALE 306 trial met primary endpoint at interim analysis, demonstrating tislelizumab plus chemotherapy significantly improved overall survival compared to chemotherapy alone in patients with…
-
Key ReleaseNovartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlookAd hoc announcement pursuant to Art. 53 LR Q1 sales grew +5% (cc1, +1% USD), core operating income grew +9% (cc, +3% USD) Innovative Medicines (IM) sales grew +4% (cc, +1% USD) and core…
-
Media ReleaseNovartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancerOpinion based on Phase II GEOMETRY mono-1 study showing an overall response rate (ORR) of 51.6% in a cohort evaluating second-line patients only and 44% in all previously-treated patients with…
-
Media ReleaseSandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolioBrimonidine tartrate/timolol maleate combination eyedrop is used to treat elevated eye pressure in patients with ocular hypertension1 Ocular hypertension affects over 5% of all adults2; the…
-
Media ReleaseNovartis announces early clinical data for unique KRASG12C inhibitor at American Association for Cancer Research annual meetingJDQ443, an investigational selective, covalent, and orally bioavailable KRASG12C inhibitor, shows 57% confirmed ORR at recommended dose of 200 mg twice daily in Phase Ib study in patients with…
Pagination
- ‹ Previous page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- …
- 88
- › Next page